ReviewDermatology and therapy2023
Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status.
Review in Dermatology and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- Cost-effective omalizumab dosage for chronic urticaria: a systematic review and network meta-analysis.Archives of dermatological research · 2024Pooled it
- A comprehensive analysis on the safety of two biologics dupilumab and omalizumab.Frontiers in medicine · 2024Pooled it
- Chemistry, pharmacology and spotlight on the clinical trials of remibrutinib: a first in class, oral Bruton's tyrosine kinase (BTK) inhibitor for chronic spontaneous urticaria.Molecular diversity · 2026Review
- Shared Mechanistic Pathways in Bullous Pemphigoid, Chronic Spontaneous Urticaria, Prurigo Nodularis, and Chronic Prurigo of Unknown Origin: Implications for Targeted Therapies.American journal of clinical dermatology · 2026Review
- Family quality-of-life burden in chronic spontaneous urticaria: A multicentre study.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Unmet Needs in Treatment Escalation for Chronic Spontaneous Urticaria: Findings From the CURE Registry.Allergy · 2026Article
- Omalizumab-Associated Post-Injection Urticaria Exacerbation and Urticaria-Related Adverse Reactions During Treatment for Chronic Urticaria: A Scoping Review.Life (Basel, Switzerland) · 2026Review
- Real-world efficacy and safety of omalizumab in chronic spontaneous urticaria: Insights from the Middle East.The journal of allergy and clinical immunology. Global · 2026Article
- An opportunity to improve the quality of care for patients with chronic spontaneous urticaria: A reimagined 3-step real-world study protocol.The journal of allergy and clinical immunology. Global · 2026Article
- Targeting Mast Cells in Chronic Spontaneous Urticaria.Current allergy and asthma reports · 2026Review
- Advancements and challenges in the management of chronic inducible urticaria.Frontiers in immunology · 2026Review
- Comparison of two omalizumab dose-reduction strategies in patients with chronic spontaneous urticaria during the control phase: standard dose maintenance therapy versus extended interval dose reduction.American journal of translational research · 2026Article
- Specialist care improves diagnosis and treatment for patients with chronic spontaneous urticaria: A real-world survey.The journal of allergy and clinical immunology. Global · 2026Article
- Unexpected analgesic effect of omalizumab in a patient with chronic widespread pain.Clinical rheumatology · 2026Article
- How to manage hypersensitivity reactions to enzyme replacement therapy in lysosomal storage diseases?Orphanet journal of rare diseases · 2025Review
- Type 2 Inflammation and Its Role in Dermatologic Diseases.International journal of dermatology · 2025Review
- Quality of life, sleep, and psychological well-being in chronic spontaneous urticaria patients receiving omalizumab: a case-control study.Archives of dermatological research · 2025Article
- Eosinophil-Driven vs. Eosinophil-Associated Severe Asthma: Practical Implications for Target Treatment.International journal of molecular sciences · 2025Review
- Antihistamines and omalizumab combination treatment in patients with chronic spontaneous urticaria: Real-world experience from a tertiary care hospital.Northern clinics of Istanbul · 2025Article
- Therapies for Chronic Spontaneous Urticaria: Present and Future Developments.Pharmaceuticals (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic spontaneous urticaria (CSU) is a debilitating inflammatory disorder of the skin, characterized by a fluctuating natural history, a complex mechanism of action, and a significant burden on patients, including effect on quality of life, development of psychosocial disorders, and a range of comorbidities. Recent international guidelines recommend a therapeutic approach of first-line treatment with second generation H1-antihistamines and second-line treatment with the biologic omalizumab. Here, the salient aspects of CSU and current status of data for omalizumab for patients with CSU are reviewed, with a focus on mechanism of action, efficacy and real-world effectiveness (including patient outcomes, response, relapse, and remission), and safety (including consideration of the risk of anaphylaxis). The review also considers recent data on COVID-19, CSU, and omalizumab and presents our perspective on future needs. Overall, the data suggest that omalizumab is an effective and well-tolerated treatment for patients with CSU that provides benefits for a wide range of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.